Details
Category: Volume 05 Issue 08 August 2017
Hits: 1677

Title: CEA and CA19-9 in Recurrence and in Monitoring Response in Gastric Carcinoma

Authors: Ranjit.S.Ambad, Dr Sanjay Agrawal, Dr Suryakant Nagtilak

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i8.112

Abstract

Aim:  To analyze the level of serum Carcinoembryonic antigen (CEA) and CA19-9 before and after treatment.

Methods: For the study comprising total 60 cases suffering from gastric carcinoma before and after different cycle of treatment were selected. All patients were clinically and histologically diagnosed. A total of 50 age and sex matched healthy subjects taken as control. The circulating levels of CEA and CA19-9 activity were assayed in the in the serum of control group and in patients with Gastric carcinoma.

Results: The activity of CEA and CA19-9 was significantly highly increased found in gastric carcinoma patients compare to normal control. In normal healthy control the CEA and CA 19-9 activity was 1.95 ± 0.45, 23.94 ± 9.17 and in patients group 12.52 ± 4.37, 63.93 ± 16.72 respectively and the sensitivity of CEA in gastric carcinoma patients was 31.94 % and CA 19-9 was 42.56%. The combined detection of CEA and CA19-9 had higher sensitivity and specificity in gastric carcinoma patients. The level of CEA and CA19-9 were related to histological type or staging of malignancy. Compared with preoperative concentration, the level of CEA and CA19-9 significantly decreased 4 weeks after treatment or operation. It shows that the tumor is completely removed or a patient gives response to treatment or it shows disease is not recurrence or metastasized. When metastasis and recurrence occurred, the level of CEA and CA19-9 highly significantly increased found. Increased level of Tumor marker like CEA and CA19-9 indicates poorer survival.

Conclusion: CEA is a tumor marker that is measured using a blood test.CEA tumor marker is one of the general type tumor markers. A multiply increased CEA levels in the blood indicate to the presence of a malignant disease in the body, but not to the organ in which the malignant change has occurred. High levels of CEA may indicate that cancer has spread; however, other medical conditions and some treatments, including certain types of chemotherapy, may raise CEA levels. The conclusion of the study was that tumor markers can be useful in monitoring the response to treatment and in estimating the prognosis of disease and the combination of CEA and CA19-9 may be useful in diagnosis and management of patients with gastric carcinoma. The various types of biological behaviors of gastric carcinoma need further studies on molecular basis of tumor cells and tumor markers.

Keywords: Gastric carcinoma, CEA, GI tract, CA19-9, DNS, NCRP, Colorectal, Gastric, Esophagus, Liver, Gallbladder and Pancreas, Surgery radiotherapy, Immunotherapy. Chemotherapy.

References

  1. Boyle P, Ferlay J., Cancer incidence and mortality in Europe. Journals of oncology, 2005; 16 (3): 481-8.
  2. Ferlay J. Shin HR. Bray F et. al. Estimation of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int. J. Cancer (2010) 127(12): 2893-2917.
  3. Last accessed on 2016 Feb 16]. Available from: http: www.globocan.iarc.
  4. Dikshit R. Gupta P, Ramasundarahettige C. et.al. “Cancer mortality in India: A nationally representative survey”. Lancet 2012379 (9828): 1807-16.
  5. Rao D.N. et.al. Estimation of cancer incidence in India Ind. J. cancer 1998.
  6. NCRP (2009) two years report of the population based cancer registries. 2006-2008. National cancer registry programme. Indian council of medical Research (ICMR). Bangalore India 2009.
  7. NCRP (2013). Three years report of the population based cancer registries 2009-2011. National cancer registry programme Indian Council of Medical Research. Bangalore. India 2013.
  8. Rajesh P. Dikshit, Garima Mathur, Sharayu Mhatre and B.B. Yeole. Epidemiological review of gastric cancer in India. Indian J.Med.Pead.Oncol. 2011 Jan-Mar; 32(1): 3-11.
  9. Helbock HJ, Beckman KB, Shigenaga MK, Walter PB, Woodall AA, Yeo HC, Ames BN.DNA oxidation matters. The HPLC-electrochemical detection assay of 8-oxodeoxyguanosine and 8-oxo-guanine. Prac. Nat Acad Sci USA, 1998; 95:288-293.
  10. Anand P, Ajaykumar BK, Sundaram C, et.al. Cancer is a preventable disease that requires major lifestyle changes. Pharma Res 2008;25: 2097-2116.
  11. Thomas SN, Zhu F, Schnaar RL, Alves CS, Kontantopoulos K. Carcinoembryonic antigen and CD 44 variant isoforms co-operate to mediate colon carcinoma cell adhesion to E and L-Selectin in shear Flow J Biol. Chem 2008; 283: 15647-15655.
  12. Kontantopoulos K, Thomas SN. Cancer cell in transit; the vascular interactions of tumor cells annu. Rev,Biomed. Eng 2009; 11: 177-202.
  13. Chan DW, Sell S. Tumor marker In Clinical chemistry 3rd edition Saunders Philadelphia 199; pp 734.
  14. Takahashi Y, Takeuchi T, Sakamoto J et. al. The usefulness of CEA and CA 19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric cancer 2003; 6: 142-145.
  15. Gold P, Freedom SO. Demonstration of tumor specific antigen in human colonic carcinoma by immunological tolerance absorption techniques. J Exp Med. 1965; 121: 439-462.
  16. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142-145.
  17. Staab HJ, Anderer FA, Brummendorf T, Hornung A, Fischer R. Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancer. Br J Cancer. 1982;45:718-727.
  18. Dittrich C, Jakesz R, Havelec L, Lenzhofer R, Breyer S, Moser K. Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients. Cancer Detect Prev.1985;8:181-187.
  19. Tamada R, Hiramoto Y, Tsujitani S, Nozuka T, Okamura T, Masuda H, et al. Serum CEA levels facilitate detection of recurrences of of cancer in patients after gastrectomy. Jpn J Surg. 1985;15:23-29
  20. Sakamoto J, Nakazato H, Teramukai S, Ohashi Y, Takahashi Y, Mai M, et al. Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative  Tumor Marker Committee, Japanese Foundation  for Multidisciplinary Treatment of Cancer, Tokyo, Japan. Surg Oncol. 1996;5:133-139
  21. Nakane Y, Okamura S, Akehira K, Boku T, Okusa T, Tanaka K, et al. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. Cancer. 1994;73:2703-2708.
  22. Erdal Polat, Ugur Duman, Mustafa Duman et.al Preoperative serum tumor marker levels in Gastric Cancer. Pak J Med Sci 2014 Vol. 30 ( 1). 145-149.
  23. Xavier Filelle, Jose Fuster, Rafeal Molina et. al. TAG-72, CA19-9 and CEA as a tumor marker in Gastric cancer. Acta Oncologia 1994. 33(7); 747-751.
  24. Magnani JL, Nilsson B, Brockhaus H, et al: A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982;257:14365–14369.
  25. Atkinson B, Ernst C, Herlyn M, et al: Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer 1982;42:4820–4823.
  26. Dilege E, Mihmanli M, Demir U, et al: Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. Hepatogastroenterology 2010;57:674–677.
  27. Gunnellini M, Granziosi L, Emili R, et al: Metastatic gastric cancer successfully treated with surgery and chemotherapy. Case report. G Chir 2010;31:375–378
  28. Jie-Xing Jing, Yan Wang, Xiao-Qin Xu, Ting Sun Bao-GuoTian, Li Li Du, Xian-Wen Zhao, Cun-Zhi Han. Tumor markers for diagnosis, monitoring and recurrence and prognosis in patients with upper gastrointestinal tract cancer. Asian Pac J Cancer Prev 2014; 15(230: 10267-1027.

Corresponding Author

Ranjit S. Ambad

Assistant Professor Dept. of Biochemistry, CCM Medical College, Kachandur, Durg (CG) 490024

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Mob no. 09917999919